Fund moves

NeoGenomics Laboratories, Inc. (NEO): Bridgewater Associates opened a new position $677K

Bridgewater Associates opened a new position in NeoGenomics Laboratories, Inc., per its Q1 2026 13F.

91K
Shares reported
0.00%
Disclosed portfolio weight
$677K
Reported value
Holdings as of
Mar 31, 2026
Filed
May 15, 2026

What stands out in this filing

  • A new position in Q1 2026: 91,190 shares, none in the manager's Q4 2025 filing.
  • 1 other tracked manager reported the same kind of change for Q1 2026.

Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Apr 24, 2026Federal contract · $644K obligatedDepartment of Veterans Affairs awarded NEOGENOMICS INC: $644K obligated to date
  2. Apr 28, 2026Company filing · Form 8-K · ResultsReported its results

What came next

  1. May 21, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“On May 21, 2026, NeoGenomics, Inc. (the "Company") held an annual meeting (the "Annual Meeting") of its stockholders. At the Annual Meeting, stockholders approved an amendment (the "Amendment") to the Company's 2023 Equity Incentive Plan (the "Equity Incentive Plan") to increase the number of shares authorized for issuance thereunder by 5,000,000 shares.”
  2. May 22, 2026Federal contract · $402K obligatedDepartment of Health and Human Services awarded NEOGENOMICS INC: $402K obligated to date
  3. Jun 11, 2026Federal contract · $100K obligatedDepartment of Veterans Affairs awarded NEOGENOMICS INC: $100K obligated to date
  4. Jun 16, 2026Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations (and 2 more items)
  5. Jun 17, 2026Federal contract · $494K obligatedDepartment of Veterans Affairs awarded NEOGENOMICS INC: $494K obligated to date
  6. Jun 23, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On June 23, 2026, the Board of Directors (the "Board") of NeoGenomics, Inc. (the "Company") increased the size of the Board from nine to ten directors and appointed Carolyn S. Starrett as a director to fill the newly created vacancy, effective immediately.”
  7. Jul 28, 2026Company filing · Form 8-K · ResultsReported its results
  8. Aug 7, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On August 11, 2026, NeoGenomics, Inc. (the “Company”) announced that Alicia Olivo, EVP, General Counsel & Business Development, would transition from her role with the Company and cease to serve as General Counsel effective as of September 21, 2026.”
  9. Aug 7, 2026CongressDisclosed purchase of NEO — reported range $1,001 - $15,000
View the official recordSEC Form 13F-HR

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for NeoGenomics Laboratories, Inc.

For NeoGenomics Laboratories, Inc., OQRO holds 1 Congress trade report dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its NEO page.

How this filing works

Explore the data

Common questions

What does this filing report about NeoGenomics Laboratories, Inc. (NEO) stock?

Bridgewater Associates opened a new position in NeoGenomics Laboratories, Inc., per its Q1 2026 13F. 91K shares reported, 0.00% of disclosed portfolio.

When did it happen, and when was it made public?

Holdings as of: Mar 31, 2026. Filed: May 15, 2026.

What stands out in this filing?

A new position in Q1 2026: 91,190 shares, none in the manager's Q4 2025 filing. 1 other tracked manager reported the same kind of change for Q1 2026.

Is this a trade made on a known date?

No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.

Where does this information come from?

From the SEC Form 13F-HR, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about NeoGenomics Laboratories, Inc. recently?

For NeoGenomics Laboratories, Inc., OQRO holds 1 Congress trade report dated in the last 90 days. They are listed on the NEO page.

Does this mean NEO stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at NeoGenomics Laboratories, Inc.

Everything OQRO holds on this company is on its NEO page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data